Listed by the USPTO as DUFFY, BRADLEY
Tech Center 1600 • Art Units: 1638 1643
This examiner grants 54% of resolved cases
DUFFY, BRADLEY is a USPTO patent examiner in tech center 1600 and art unit 1638. The profile records 754 resolved cases, a 54.4% allowance rate, and a median of 1361 days to allowance. Interviews are associated with a 46.0% lift, making interview preparation a material consideration for prosecution strategy in this docket.
The listed company matters include Amgen Inc., Bms, and University of Florida Research Foundation Inc. The listed firms are FOLEY & LARDNER LLP, MORRISON & FOERSTER LLP, and Casimir Jones, S.C. Practitioners handling matters here can use the interview result alongside the allowance and pendency figures when deciding whether to prioritize examiner engagement.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17575762 | CHIMERIC ANTIGEN RECEPTOR COMPRISING INTERLEUKIN-15 INTRACELLULAR DOMAIN AND USES THEREOF | Final Rejection | University of Florida Research Foundation, Incorporated |
| 19447763 | Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods Therefor | Non-Final OA | AlbuNext, LLC |
| 18280561 | PROGNOSTIC PATHWAYS FOR HIGH RISK SEPSIS PATIENTS | Non-Final OA | KONINKLIJKE PHILIPS N.V. |
| 19393395 | LONG ACTING ALPHA4BETA7 TARGETING MOLECULE COMPOSITIONS FOR THE TREATMENT GASTROINTESTINAL INFLAMMATORY DISEASE | Non-Final OA | Paragon Therapeutics, Inc. |
| 16981168 | CELLULAR SIGNALING DOMAIN ENGINEERING IN CHIMERIC ANTIGEN RECEPTOR-MODIFIED REGULATORY T CELLS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18691685 | COMPOSITIONS OF CHIMERIC ANTIGEN RECEPTOR (CAR) SIGNALING MOLECULES AND USES THEREOF | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18491633 | METHODS AND COMPOSITIONS FOR ADOPTIVE CELL THERAPY | Final Rejection | Juno Therapeutics, Inc. |
| 17588149 | METHODS AND COMPOSITIONS FOR ADOPTIVE CELL THERAPY | Non-Final OA | Juno Therapeutics, Inc. |
| 18169293 | AMHR2-ED CANCER VACCINE FORMULATIONS | Final Rejection | The Cleveland Clinic Foundation |
| 17775063 | ENGINEERING CHARGE PAIR MUTATIONS FOR PAIRING OF HETERO-IgG MOLECULES | Final Rejection | AMGEN INC. |
| 18164304 | TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA | Non-Final OA | AMGEN RESEARCH (MUNICH) GMBH |
| 18066972 | CROSS-SPECIES-SPECIFIC BINDING DOMAIN | Non-Final OA | Amgen Research (Munich) GmbH |
| 18689483 | CD28 SHEDDING BLOCKING AGENTS | Non-Final OA | BIOND BIOLOGICS LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy54.4% of resolved applications examined by Bradley Duffy were allowed (754 resolved cases), compared with 48.8% across Art Unit 1638 over the last five years.
This examiner's interview lift is +46.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Bradley Duffy took 1,361 days on average from filing to allowance.
Bradley Duffy examines applications in Art Unit 1638 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
